Cramer's Mad Money - Time Is Up For Treasurys (2/7/12)

 |  Includes: ABMD, CSX, NSC, TLT, UNP
by: Miriam Metzinger

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday February 7.

Treasurys Are Topping: iShares Barclay's 20+ Treasury Bond ETF (NYSEARCA:TLT)

Treasurys were the best performing asset class of 2011, returning 30% for the year. However, bonds might have peaked, and according to the charts, they might be in for a dramatic decline. The chart of the iShares Barclay's 20+ Treasury Bond ETF (TLT) is showing lower highs, according to the Relative Strength Index. The TLT could be falling below the floor of support. The daily chart is showing many ceilings of resistance with fewer levels of support underneath. There could be a 10% decline in the TLT, which is no longer trading in lockstep with the Volatility Index. The TLT may be a short if it falls below $116. Cramer would get out of bonds and invest in stocks.

Union Pacific (NYSE:UNP), Norfolk Southern (NYSE:NSC), CSX (NYSE:CSX)

The rails are a good play on a booming economy, but which stock is worth buying? Norfolk Southern (NSC) seems like a cheaper stock, since it trades at a multiple of 12 with a 16% growth rate; UNP also has a growth rate at 16% but has a slightly higher multiple of 14. However, Cramer thinks UNP is a stock worth paying up for, since it is less levered to the troubled coal industry than NSC. UNP might have rallied 44% since October, compared to NSC's increase of 20%, but UNP has more advantages, since it will benefit more from repricing of expired contracts than NSC. UNP's quarter saw an 18 cent earnings beat on a 15.8% rise in revenues, whereas NSC missed earnings estimates. UNP has better management, a cleaner balance sheet and is a buy.

Cramer took a call:

CSX (CSX) has strong management, but it is heavily levered to coal, and with declining natural gas prices, exposure to coal is bad for rail stocks.

CEO Interview: Michael Minogue, Abiomed (NASDAQ:ABMD)

Abiomed (ABMD) has produced the world's smallest heart pump, a minimally invasive catheter that can be inserted into the leg. The treatment has the potential of generating $1 billion for ABMD and can help patients keep their own hearts, and reduce the number of transplants. The company beat earnings by 7 cents and reported an 18% increase in revenues. The stock is up 23% since the beginning of the year. Rumors that insurance companies might cut their coverage of the pump are untrue, according to Michael Minogue. Patients who use the heart pump see 56% fewer adverse reactions after treatment, and it is an inexpensive and effective treatment. Cramer likes ABMD as a speculative stock.


Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.